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Pheochromocytoma Requires Adjustment of Urinary
and Plasma Metanephrine Reference Ranges
Thamara E. Osinga,* Maartje H. A. van den Eijnden,* Ido P. Kema,
Michiel N. Kerstens, Robin P. F. Dullaart, Wilhelmina H. A. de Jong,
Wim J. Sluiter, Thera P. Links, and Anouk N. A. van der Horst-Schrivers
Departments of Endocrinology and Metabolic Diseases (T.E.O., M.H.A.v.d.E., M.N.K., R.P.F.D., W.J.S.,
T.P.L., A.N.A.v.d.H.-S.) and Department of Laboratory Medicine (I.P.K., W.H.A.d.J.), University of
Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands
Context: Follow-up after adrenalectomy for pheochromocytoma is recommended because of a
recurrence risk. During follow-up, plasma and/or urinary metanephrine (MN) and normetaneph-
rine (NMN) are interpreted using reference ranges obtained in healthy subjects.
Objective:Becauseadrenalectomymaydecreaseepinephrineproduction,wecomparedMNandNMN
concentrations in patients after adrenalectomy to concentrations in a healthy reference population.
Design: A single-center cohort study was performed in pheochromocytoma patients after adre-
nalectomy between 1980 and 2011.
Subjects: Seventy patients after unilateral and 24 after bilateral adrenalectomy were included.
Main Outcome Measures: Plasma-free and urinary-deconjugated MN and NMN determined at 3
to 6 months and annually until 5 years after adrenalectomy were compared with concentrations
in a reference population. Data are presented in median (interquartile range).
Results: Urinary and plasma MN concentrations 3 to 6 months after unilateral adrenalectomy were
lower comparedwith the reference population (39 [31–53] mol/mol creatinine and 0.14 [0.09–0.18]
nmol/L vs 61 [49–74] mol/mol creatinine and 0.18 [0.13–0.23] nmol/L, respectively, both P  .05).
UrinaryMNafterbilateral adrenalectomywas reducedeven further (7 [1–22]mol/mol creatinine;P
.05). Urinary and plasma NMN were higher after unilateral adrenalectomy (151 [117–189] mol/mol
creatinine and 0.78 [0.59–1.00] nmol/L vs 114 [98–176] mol/mol creatinine and 0.53 [0.41–0.70]
nmol/L; bothP .05).UrinaryNMNafterbilateral adrenalectomywashigher (177 [106–238]mol/mol
creatinine; P .05). Changes in urinary and plasma MNs persisted during follow-up.
Conclusion: Concentrations of MN are decreased, whereas NMN concentrations are increased after
unilateral andbilateral adrenalectomy. Adjusted reference values forMNandNMNare needed in the
postsurgical follow-upofpheochromocytomapatients. (J Clin EndocrinolMetab98: 1076–1083, 2013)
Pheochromocytomas are rare catecholamine-producingtumors, derived from adrenal chromaffin tissue (1).
Pheochromocytomas occur sporadically or as part of several
hereditary tumor syndromes, such as multiple endocrine
neoplasia (MEN) type2,vonHippel-Lindausyndrome,neu-
rofibromatosis type 1 and in the context of succinate dehy-
drogenase (SDH) mutations (2). In pheochromocytoma pa-
tients, the demonstration of excessive production of
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catecholamines and their 3-O-methylated metabolites,
metanephrine (MN) and normetanephrine (NMN), consti-
tutes the cornerstone of biochemical diagnosis (3–5). In
healthy individuals, the adrenal medulla together with the
sympathetic nervous system represent the main sources of
catecholamine production and metabolism (6) (Figure 1).
Cortisol from the adrenal cortex enhances the activity of phe-
nylethanolamine-N-methyltransferase (PNMT; EC 2.1.1.28)
(7, 8). Because the enzymatic conversion of norepinephrine to
epinephrine by PNMT is cortisol-dependent, the adre-
nal medulla is main source of MN measured in urine
and/or plasma (6, 9).
Resection of a pheochromocytoma through adrenalec-
tomy is indicated to prevent potentially fatal complications
due to catecholamine excess (10, 11). Postoperatively, peri-
odicmeasurement of plasma and/or urinaryMNandNMN
is performed to monitor for recurrent disease. Follow-up is
recommended 2 to 3months postoperatively, annually dur-
ing the first 5 years, and once every 2 years thereafter (12).
During long-term follow-up, 6%–16% of tumors recur
within 10 years postoperatively, but tumor recurrences have
been described even after 15 years (13–15). Follow-up is es-
pecially important for patients with hereditary tumor syn-
dromes, because these individuals have an increased risk for
developing a pheochromocytoma in the contralateral adre-
nal gland (13, 14).
In routine clinical practice, the con-
centrations of urinary and/or plasma
MNandNMNfound inpatients after
adrenalectomy are interpreted by us-
ing reference intervals established in
healthy subjects. However, unilateral
or bilateral adrenalectomy is expected
tobe followedbyadecreaseof epineph-
rine and, consequently, lower plasma
andurinaryMNconcentrations.Use of
incorrect reference intervals may inter-
ferewithearlydetectionof tumor recur-
rence, eg, when the associated rise in
MN concentration occurs within the
reference rangeapplicable tohealthy in-
dividualswithnormally functioningad-
renal glands. Currently, there is no de-
tailed information on the influence of
adrenalectomyonepinephrine andnor-
epinephrine concentrations.
Therefore, the aim of this cohort








We retrospectively studied patients above 20 years of age at
the time of diagnosis who had undergone either bilateral or uni-
lateral adrenalectomy for pheochromocytoma at the University
MedicalCenter ofGroningenbetween January 1980 andAugust
2011. This period was chosen because assays of fractionated
totalMNs in urinewith gas chromatography-mass spectrometry
and plasma fractionated free MNs with liquid chromatography
tandem mass spectrometry (LC-MS/MS) have been available at
our institution since 1979 and 2005, respectively. The diagnosis
of a pheochromocytoma was histologically confirmed in all pa-
tients. Postoperative concentrations of MNs had to be available
for at least 1 follow-up visit after adrenalectomy. Exclusion cri-
teria were a recurrent tumor within 5 years of surgery, a partial
(ie, cortical-sparing) adrenalectomy, and incomplete resection of
the tumor. Patients who presented with a concurrent extra-ad-
renal paraganglioma were also excluded. Preferably, tumor re-
currence had to be confirmed by histology. In cases lacking this
information, a diagnosis of tumor recurrence was based on the
combined results of anatomical and functional imaging.
The initial clinical diagnosis of a pheochromocytoma was
based on elevated urinary and/or plasma MN and NMN con-
centrations and localization of the tumor with anatomical im-
aging of both adrenal glands (computed tomography/magnetic
resonance imaging) as well as whole-body functional imaging






























Figure 1. Schematic representation of catecholamine synthesis and metabolism pathway inside
the adrenal gland. Dopamine, norepinephrine, and epinephrine are synthesized inside the
adrenal medulla. DOPA is converted to dopamine by the aromatic L-amino acid decarboxylase
(AADC; EC 4.1.1.28) enzyme. Dopamine is converted by the dopamine -hydroxylase (DBH; EC
1.14.17.1) enzyme to norepinephrine, which is finally converted to epinephrine by the PNMT
enzyme. PNMT is stimulated by cortisol from the adrenal cortex. The catecholamines are
metabolized by the catechol-O-methyltransferase (COMT; EC 2.1.1.6) enzyme and can be
measured as 3-methoxytyramine (3-MT), NMN, and MN in plasma. The MNs are sulfated by the
sulfotransferase isoenzyme 1A3 (SULT1A3; EC 2.8.2.1). The sulfated (conjugated) MNs and the
free (unconjugated) MNs are measured in urine. Abbreviations: PAH, phenylalanine hydroxylase
(EC 1.14.16.1); TH, tyrosine hydroxylase (EC 1.14.16.2).
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with [123I]metaiodobenzylguanidine (MIBG) scintigraphy or
[18F]dihydroxyphenylalanine (DOPA) positron emission to-
mography (PET) (available at our institution since 2003). Long-
term follow-up was performed by measurement of urinary
and/or plasmaMNs. Anatomical and/or functional imagingwas
repeated in patients with persistently elevated MNs to localize
recurrent disease. In accordance with international guidelines,
patients below50yearsof agewere tested for germlinemutations
(16–19). In patients above 50 years of age, the family historywas
checked to evaluate the risk for hereditary syndromes.
For all patients, the following data were retrieved from their
medical files: symptoms (headache, abdominal complaints, pal-
pitations, paleness, flushes, vertigo, nausea, and anxiety), signs
related to a pheochromocytoma (blood pressure [BP] and pulse
rate) at presentation, pre- and postoperative use of medication,
and results of germline mutation analysis. Hypertension was
defined as a systolic BP of140 mmHg and/or a diastolic BP of
90 mm Hg or the use of antihypertensive medication. Addi-
tionally, we evaluated surgical and pathology reports of all the
patients included in the study to confirm complete resection of
the adrenal medulla. Because of the retrospective nature of this
study and the use of clinical data, no further Institutional Review
Board approval was required, according to the Dutch Medical
Research Involving Human Subjects Act.
The concentrations of urinary and/or plasma MN and NMN
were collected pre- and postoperatively, at 3 to 6 months and an-
nually up to 5 years. The main outcome measure was the concen-
tration of urinary or plasmaMN and NMN concentration at 3 to
6monthsafterunilateralorbilateral adrenalectomy.Bloodsamples
were collected by venipuncture, with patients in seated position, in
10-mL Vacutainer tubes (Becton Dickinson, Franklin Lakes, New
Jersey) containing K2-EDTA solution as anticoagulant.
Reference values for deconjugated urinary MN and NMN
concentrationswere established in a groupof 60healthy subjects
(30 men and 30 women, 20–70 years of age), as reported pre-
viously byWillemsen et al (20). Reference values for plasma free
MN and NMN concentrations were determined in a group of
120 healthy subjects (63 men and 57 women, 36–81 years of
age) participating in the Prevention of Renal and Vascular End
Stage Disease (PREVEND) study (21, 22). Healthy subjects taking
antihypertensive medication were not included. Measurement of
plasma and urinary MN concentrations in both healthy subjects
and patients was performed without prior dietary restrictions.
Analytical methods
Isotope-dilution mass spectrometry-based measurements of
urinary and/or plasma MNs were used. Urinary deconjugated
MN concentrations were determined by isotope-diluting gas
chromatography-mass spectrometry, as described byMuskiet et
al (23, 24). Urinary deconjugatedMN concentrations were nor-
malized to the urinary excretion of creatinine, measured using a
picric acid-basedmethod (before 2005) or an enzymatic method
(Roche Diagnostics, Almere, The Netherlands) (after 2005) and
expressed in units of micromoles per mole of creatinine. The
intra-assay variation coefficient was 1.7%–4.2%, and the inter-
assay variation coefficient was 3.3%–15.4%. Reference inter-
vals for urinary MNs were as follows: MN, 33–99 mol/mol
creatinine; NMN, 64–260 mol/mol creatinine.
Plasma free MN assays were performed with a HPLC tandem
mass spectrometric technique (LC-MS/MS) with automated solid-
phase extraction sample preparation, as described by de Jong et al
(22). Established reference intervals for plasma free MNs were as
follows: MN, 0.07–0.33 nmol/L; NMN, 0.23–1.07 nmol/L. The
intra-assay and interassay variation coefficients were 2.5%–4.8%
and 3.4%–5.6% for the free plasmaMNmeasurement and 5.1%–
6.2% and 4.2%–7.1% for the free plasma NMNmeasurement.
Statistics
DataarepresentedasmeanSDorasmedianwith interquartile
ranges where appropriate. Differences between urinary MNs in
healthy subjects and patients after unilateral or bilateral adrenal-
ectomy were evaluated using the Mann-WhitneyU test with Bon-
ferroni correction. AMann-WhitneyU test was performed to cal-
culate thedifferencesbetweenthereferencepopulationandpatients
after unilateral adrenalectomy for the plasma MNs. Baseline was
defined as 3 to 6months after adrenalectomy. For each individual,
a Spearman correlation coefficient was calculated regarding the
relationship of the respective plasma and urinaryMNs concentra-
tions with follow-up time (ie, baseline and the various follow-up
time points). Subsequently, averaged correlation coefficients were
calculated after Fisher’s Z-transformation using the correlation co-
efficients per patient. We also calculated the percent changes in
plasma and urinary MNs at the various follow-up moments com-
pared with baseline. A two sided P value .05 was considered
statistically significant. Statistical analyses were performed with
PASW statistics (version 18.0; IBM/SPSS, Armonk, New York).
Results
Patient characteristics
Between January 1980 and August 2011, 108 pheochro-
mocytoma patients underwent a unilateral or bilateral adre-
nalectomy at our institution. Of these, 14 patients (13.0%)
were excluded. Reasons for exclusion were missing labora-
tory data (n  4), subtotal adrenalectomy (n  1), and re-
current disease (n 9) within 5 years after adrenalectomy.
Table 1 shows the preoperative characteristics of all patients
included in the study. In 2 patients (2.1%) with a sporadic
pheochromocytoma, no functional imagingwas performed.
Seventypatients (74.5%)underwent aunilateral adrenal-
ectomy. Median follow-up time for these patients was 39.2
(14.9–86.2) months. During follow-up, 4 patients (5.7%)
died (cardiovascular disease, n 1; malignancy, n 2; un-
known cause, n 1) after a median follow-up time of 17.0
(3.9–30.5) months. Twelve patients (17.1%) were referred
to other centers for continuationof follow-up after amedian
19.6 (8.4–49.0) months.
Twenty-four patients (25.5%) underwent a bilateral ad-
renalectomy. The median follow-up time was 169.5 (56.8–
235.4) months. During follow-up, 4 patients (16.7%) died
(malignancy, n1; gastrointestinal bleeding, n1; suicide,
n 1; unknown cause, n 1) after amedian period of 42.6
(3.3–132.1)months, and in 1 patient (4.2%), follow-upwas
continued at another center after 128.4 months.
Preoperatively, all patients were treated with adrenergic
receptor antagonists to prevent potentially fatal complica-
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tions of surgery. At 3 to 6 months after adrenalectomy, 24
patients (25.5%) used antihypertensive medication, of
whom 13 used -adrenergic receptor antagonists (13.8%).
Postoperative deconjugated urinary and plasma
free MN concentrations
In patients who underwent a unilateral adrenalectomy,
themedian urinary and plasmaMNconcentrationwere sig-
nificantly lower3to6monthsafterunilateraladrenalectomy
compared with the reference population (both P .05), as
shown in Table 2. Themedian urinaryMN concentration 3
to 6 months after unilateral adrenalectomy was 36.1%
(13.1%–49.2%) lower, whereas the median plasma MN
concentration was 22.3% (0.0%–50.0%) lower compared
with the median values in the reference population. In 19
patients (33.9%), the urinaryMNconcentrationwas below
the lower reference limit (LRL)3 to6months after unilateral
adrenalectomy. The plasma MN concentration was below
the LRL in 2 patients (6.7%) 3 to 6months after adrenalec-
tomy. During the 5-year follow-up, there was a median in-
crease of the urinaryMNconcentration of 11.1% (8.5%–
36.9%) compared with baseline values (defined as 3 to 6
months after adrenalectomy) (averaged correlation coeffi-
cient, 0.37; P .05). This correlates to a small absolute in-
crease of the median urinaryMN concentration from 39 to
43 mol/mol creatinine. There were no changes over the
5-year time frame in plasma MN (averaged correlation co-
efficient, 0.19; P .058) (Figure 2). In patients who under-
wentabilateraladrenalectomy, themedianurinaryMNcon-
centration 3 to 6 months after adrenalectomy was 88.5%
(63.9%–98.4%) lower compared with the reference popu-
lation (P  .05) (Table 2). Fifteen patients (83.3%) had a
urinary MN concentration below the LRL 3 to 6 months
after bilateral adrenalectomy. There was a median decrease
of 55.3% (77.0%–44.6%) in urinary MN after bilateral
adrenalectomy during the 5 years of follow-up (averaged
correlation coefficient, 0.28; P  .05) (Figure 3). The
plasmaMN concentration was available for only 2 patients
andwas0.01and0.03nmol/Lat3 to6months, respectively;
therefore, no statistical comparisonwasmade (Table2).The
urinaryMNconcentrationof17patientswithMENtype2A
3 to 6 months after bilateral adrenalectomy was 4 (1–11.8)
mol/mol creatinine, which was lower compared with the
reference population (P .05).
Postoperative deconjugated urinary and plasma
free NMN concentrations
Median urinary and plasmaNMN concentrations in pa-
tients after unilateral adrenalectomy were higher compared
with the reference population 3 to 6 months after unilateral
adrenalectomy (bothP .05) (Table2).Themedianurinary
NMN concentration 3 to 6months after unilateral adrenal-
ectomy was 32.5% (2.6%–65.8%) higher compared with
the median value in the reference population, whereas the
median plasma NMN concentration was 47.2% (11.3%–
88.7%) higher. The urinary NMN concentration 3 to 6
months after unilateral adrenalectomywas above the upper
reference limit (URL) in 6 patients (10.7%),with concentra-
tions ranging from 268 to 537 mol/mol creatinine. Four




Age, y (mean  SD) 47  16
Adrenalectomy, n (%)
Unilateral, left 33 (35)
Unilateral, right 37 (39)
Bilateral 24 (26)
Functional Imaging, n (%)
Whole-body 123IMIBG 75 (80)
Whole-body 18FDOPA PET 48 (51)
Pathology, median (IQR)
Adrenal volume, cm3 54 (30–224)
Weight, g 38.8 (21.2–121.5)
Germline mutations, n (%)
None (sporadic) 60 (64)
Familiar syndrome 34 (36)
MEN 2a 22 (65)
MEN 2b 2 (6)
VHL 5 (15)
Neurofibromatosis type 1 3 (9)
SDHB 1 (3)
SDHD 1 (3)
Main reason for referral, n (%)
Tumor on anatomical imaging 22 (23)




Known mutation carrier 23 (24)
Unknown 1 (1)
Hemodynamic control
Mean BP  SD, mm Hg 139  31/85 17
Mean pulse  SD, beats/min 81  13
Hypertension, n % 66 (70)
Antihypertensive medication, n (%) 39 (43)
-Adrenergic receptor antagonists 25 (26)
-Adrenergic receptor antagonists 14 (15)
Angiotensin-II-receptor antagonists 5 (5)
Calcium channel blockers 4 (4)
ACE inhibitors 9 (9)
Diuretics 11 (12)
Preoperative biochemistry, median (IQR)a
Urinary MN, mol/mol creatinine 898 (178–3286)
Urinary NMN, mol/mol creatinine 1160 (333–2499)
Plasma MN, nmol/L 1.03 (0.28–4.35)
Plasma NMN, nmol/L 4.31 (1.26–13.36)
Abbreviations: ACE, angiotensin-converting enzyme; SDH, succinate
dehydrogenase; VHL, von Hippel-Lindau; IQR, interquartile range.
a Reference ranges for urinary metanephrines were as follows: MN,
33–99 mol/mol creatinine; NMN, 64–260 mol/mol creatinine.
Reference ranges for plasma metanephrines were as follows: MN,
0.07–0.33 nmol/L; NMN, 0.23–1.07 nmol/L.
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patients (13.3%) had a plasma NMN concentration above
the URL 3 to 6 months after unilateral adrenalectomy.
In the 5 years of follow-up, there was a median increase
in urinary NMN concentration of 11.2% (21.6%–
22.4%) compared with the baseline values (averaged
correlation coefficient, 0.14; P  .05). There was no
change in plasma NMN after unilateral adrenalectomy
over the time frame of 5 years (averaged correlation
coefficient, 0.03; P  .788) (Figure 2).
In patients who underwent a bilateral adrenalectomy,
the median urinary NMN concentration significantly in-
creased comparedwith the referencepopulation (P .05).
Three patients (16.7%) had a urinary NMN concentra-
tion above the URL 3 to 6 months after bilateral adrenal-
ectomy with concentrations ranging from 382 to 430
mol/mol creatinine. There were no changes during the 5
years of follow-up in the urinary NMN after bilateral ad-



























































































































Figure 2. Percent changes from baseline (3 to 6 months after adrenalectomy) of urinary and plasma MNs in patients after unilateral
adrenalectomy. Baseline measurements are set at 100%. Graphs depicting the percent changes with interquartile ranges of urinary and plasma
MNs from baseline. In deconjugated urinary MN (A) and deconjugated urinary NMN (B), there was a change of 11.1% and 11.2% during 5-year
follow-up compared with baseline values (3 to 6 months after adrenalectomy). In plasma free MN (C) and plasma free NMN (D), there is no
significant change in a 5-year time frame.







Urinary MN, mol/mol creatinine 39 (31–53)b 7 (1–22)b 61 (49–74)
n 58 18 60
Plasma MN, nmol/L 0.14 (0.09–0.18)c 0.01 and 0.03 0.18 (0.13–0.23)
n 30 2 120
Urinary NMN, mol/mol creatinine 151 (117–189)b 177 (106–238)b 114 (98–176)
n 58 18 60
Plasma NMN, nmol/L 0.78 (0.59–1.00)c 0.52 and 0.67 0.53 (0.41–0.70)
n 30 2 120
a Data are shown as median (interquartile range).
b P  .05, both calculated for urinary MNs between the reference population and patients after unilateral or bilateral adrenalectomy and with
Bonferroni correction.
c P  .05, calculated for plasma MNs between the reference population and patients after unilateral adrenalectomy. Because of the low number of
patients, no comparison was made between plasma MNs after bilateral adrenalectomy and the reference population.
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.972) (Figure 3). The plasma NMN concentration was
0.52 and 0.67 nmol/L 3 to 6 months after bilateral adre-
nalectomy in the 2 patients in whom this was available.
The urinary NMN concentration of 17 patients with
MEN type 2A 3 to 6months after bilateral adrenalectomy
was higher compared with the reference population, 177
(102–232) mol/mol creatinine (P  .09).
In 17 patients (18.1%), an increased urinary and/or
plasmaNMN concentration was found during one or more
follow-up visits in the 5-year follow-up period. In 7 of these
17 patients, additional imagingwith computed tomography
(n  2), magnetic resonance imaging (n  2), [123I]MIBG
(n5), [18F]DOPAPET (n2), [111In]Octreoscan (n1),
or a clonidine suppression test (n 1) was performed with
no evidence of recurrent disease. In all of these 17 patients,
theNMNconcentration normalized during follow-upwith-
out intervention.
Discussion
In the present study, we found that MN concentrations in
both plasma and urine after unilateral and bilateral adrenal-
ectomy were persistently lower compared with the values
obtained in a reference population consisting of healthy sub-
jects. As expected, this difference was most profound in pa-
tients after bilateral adrenalectomy. In contrast, we found
that NMN concentrations in both plasma and urine in pa-
tients after adrenalectomy were higher than in healthy
subjects.
Two previous studies have described the catecholamine
and MN concentration after bilateral adrenalectomy. Shah
et al (25) demonstrated that plasma epinephrine and norepi-
nephrinewerestilldetectableafterbilateraladrenalectomyin
a small group of 5 patients with Cushing’s syndrome. Eisen-
hofer et al (26) studied 12 patients after bilateral adrenalec-
tomy, of whom 11 patients had Cushing’s syndrome and 1
patient had a pheochromocytoma. In concordance with our
study, they found that theplasmaepinephrine concentration
was below the limit of detection, and plasma concentrations
of free and conjugated MN were decreased compared with
healthycontrolsubjects.PlasmaNMNconcentrations,how-
ever, were unaffected in that study (26). It should be noted
that thepresentstudy isconsiderably larger, includespatients
after unilateral adrenalectomy, and contains long-term fol-
low-up data. Furthermore, the liquid chromatography with
electrochemical detection used in the latter study is more
susceptible to interference and has a higher detection limit
and is therefore not as accurate as the LC-MS/MS technique
we applied (27).
Although we observed a small statistically significant in-
crease of 4 mol/mol creatinine in the urinary MN concen-
tration during the 5-year follow-up, the urinary MN
concentration is persistently lower after unilateral ad-
renalectomy. This implies that the contralateral adrenal
glandcannot fully compensate for the lossofproductionand
secretion of epinephrine. The detection of MN in patients
after bilateral adrenalectomy suggests that epinephrine pro-
duction might take place outside the adrenal gland. This is
supported by the demonstration of positive immunohisto-
chemical staining for PNMT in adrenergic cells present in
fetal rat hearts and in rat adipocytes (28–30).
There might be several explanations for the observed
increase in postsurgical NMN concentrations. Most
likely, this increase is explained by an augmented produc-
tion of norepinephrine in sympathetic nerves, thereby
compensating for the loss of epinephrine activity in main-
taining vascular tone. Alternatively, this phenomenon
could also result from desensitization of - and -recep-
tors due to the high amount of circulating catecholamines
































































Figure 3. Percent changes from baseline (3 to 6 months after
adrenalectomy) of urinary MNs in patients after bilateral adrenalectomy.
Baseline measurements are set at 100%. Graphs depicting the percent
change with interquartile ranges of urinary MNs after bilateral
adrenalectomy from baseline. Deconjugated urinary MN (A) and
deconjugated urinary NMN (B) show no significant change of urinary MN
and urinary NMN in a 5-year time frame. Plasma MN and NMN
concentrations after bilateral adrenalectomy are not shown because of the
low number of patients in this group.
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and therefore expected to resolve after adrenalectomy
(31). Because patients with tumor recurrence within 5
years after surgery were excluded, the increase cannot be
attributed to a recurrent pheochromocytoma. This is ad-
ditionally supported by the observation that the increase
in NMN concentrations had already occurred 3 to 6
months postoperatively and the increase thereafter was
only marginal. False-positive results caused by analytical
interference are not likely because we used mass spectro-
metric detection, which is known for its very high analyt-
ical specificity (22). It could be argued that our results
might be confounded by preanalytical factors such as
pharmacological interference by antihypertensive drugs,
the lack of dietary restrictions, or patient positioning dur-
ing blood sampling. However, analyzing patients without
antihypertensive medication did not change the results
(data not shown). In the present study, blood was collected
while healthy subjects and patients were seated. It has been
demonstrated that plasma MNs are moderately elevated in
the seated comparedwith the supine position (32).Our con-
clusions, however,will not be affectedby thepositionduring
sampling, because the postoperative concentrations of
plasma were compared with the reference population in
whomblood samplinghadalsobeenperformed in the seated
position. In addition, the concomitant increase in 24-hour
urinary NMN concentrations argues against a possible in-
fluence of body position during blood collection. Dietary
restrictions of catecholamine-rich food supplies are consid-
ered to minimize the possibility of false-positive results for
urinary deconjugated NMN concentrations. We found de-
creased concentrations of both urinary deconjugated and
plasma free NMN concentrations. Therefore, it seems un-
likely that diet is a confounding factor (21).
Our results strongly suggest that the diagnostic yield of
the measurement of MNs in plasma or urine is negatively
affected by adrenalectomy. The decrease in MN levels is
expected to reduce the sensitivity, whereas the increase in
NMN levels after adrenalectomy is likely to lower the
specificity of this assay. Consequently, adjusted reference
intervals are needed for patients with pheochromocytoma
after unilateral or bilateral adrenalectomy. Downward
adjustment of the MN reference ranges in these patients
could thus contribute to an earlier detection of tumor re-
currence, whereas upward adjustment of the NMN ref-
erence ranges could prevent unnecessary diagnostic tests.
The latter might be particularly relevant for patients with
von Hippel-Lindau syndrome, which is accompanied by
an increased secretion ofNMN(33). According to current
knowledge, additional imaging couldhavebeenprevented
during follow-up in 7 of 94 patients (7.5%) seen in our
hospital after adrenalectomy because of a pheochromo-
cytoma. Because imaging was not performed in patients
withMNconcentrationswithin the reference intervals,we
cannot give an indication about how much sooner tumor
recurrence would have been detected with adjusted refer-
ence intervals for MN. Specific reference intervals for
urine and/or plasmaMNandNMNneed to be established
inpatients after adrenalectomy to improveboth sensitivity
and specificity for this patient group. Partial adrenalec-
tomy is an emerging alternative procedure reducing the
risk of adrenal insufficiency when performed by an expe-
rienced surgeon. Because the adrenal medulla is com-
pletely resected in partial adrenalectomy, the effects on the
catecholamine secretion after successful resection of the
pheochromocytoma are comparable with patients after
complete adrenalectomy (34, 35). We, therefore, believe
that our results are also applicable in patients after partial
adrenalectomy.
Our study has some limitations. Because of the retro-
spective nature of this study, not all data are complete.
Plasma MN concentrations after bilateral adrenalectomy
were available in only a few patients, because this partic-
ular assay was introduced in our laboratory only after
2005. Patientswith tumor recurrence after adrenalectomy
within the observation period were excluded, but fol-
low-up was shorter than 5 years in a minority of patients.
In particular, in patients with hereditary tumor syn-
dromes, tumor recurrence could not always be completely
excluded even in the absence of detectable tumor on im-
aging. Furthermore, the number of patients was too small
to perform statistical tests on the different hereditary
groups. However, analyzing patients with MEN type 2a
after bilateral adrenalectomy gave comparable results.
From these data, it can be concluded that adrenalectomy
in pheochromocytoma patients results in a new set point in
catecholamine production, with lower epinephrine and
higher norepinephrine secretion. We therefore recommend
the use of adapted reference intervals in the follow-up of
pheochromocytomapatientsafteradrenalectomy.Theseref-
erence intervalsneedtobeestablishedprospectively ina large
population of patients who have undergone surgery for a
sporadic or hereditary pheochromocytoma. These adapted
reference intervals for MNs would be expected to enable
both earlier detection of recurrent disease and prevent un-
necessary diagnostic testing.
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